Patents by Inventor Mark Zhiqing Ma

Mark Zhiqing Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOBODIES BINDING TROP2 AND USES THEREOF
    Publication number: 20230383007
    Abstract: A heavy chain only antibody that specifically binds human TROP2, or an antigen-binding portion thereof is provided. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are an immunoconjugate and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-TROP2 antibody or the antigen-binding portion thereof.
    Type: Application
    Filed: November 2, 2021
    Publication date: November 30, 2023
    Inventors: Mingjiu CHEN, Mark Zhiqing MA
  • ANTIBODIES BINDING CD40 AND USES THEREOF
    Publication number: 20230365700
    Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 16, 2023
    Inventors: Mark Zhiqing MA, Jinyu LIU, Zhengping ZHANG, Hongjiang XU
  • PD-1 BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20230331848
    Abstract: An isolated monoclonal antibody that specifically binds human PD-1, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided is a bispecific molecule and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using the anti-PD-1 antibody or the antigen-binding portion thereof.
    Type: Application
    Filed: August 30, 2021
    Publication date: October 19, 2023
    Inventors: Mingjiu CHEN, Shukai XIA, Mark Zhiqing MA, Zeyu PENG
  • ANTIBODIES BINDING IL4R AND USES THEREOF
    Publication number: 20230105029
    Abstract: An isolated monoclonal antibody that specifically binds human IL4R?, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL4R? antibody or the antigen-binding portion thereof of the disclosure.
    Type: Application
    Filed: February 25, 2021
    Publication date: April 6, 2023
    Inventors: Mingjiu Chen, Wei Tan, Cathy Xiaoyan Zhong, Mark Zhiqing Ma, Shukai Xia, Zhengping Zhang, Hongjiang Xu, Zhijian Lu